Applications of (R)-Bicalutamide in Industrial Manufacturing

(R)-Bicalutamide plays an essential role as an advanced intermediates in the synthesis of pharmaceutical agents for hormone-related oncology therapies. As a manufacturer specializing in chiral chemical raw materials, we focus on supplying (R)-Bicalutamide specifically for regulated downstream sectors with rigorously defined requirements for production standards, formulation ratios, process integration, and end-use product quality. We detail below the principal downstream application scenarios where this material delivers industrial value.

1. Active Pharmaceutical Ingredient (API) Synthesis for Anti-Androgen Cancer Drugs

The pharmaceutical sector integrates (R)-Bicalutamide as a high-purity chiral intermediate for manufacturing non-steroidal antiandrogen APIs. Its enantiomeric purity directly impacts the pharmacological targeting of finished medications used in prostate cancer therapies. Downstream pharmaceutical producers implement this intermediate according to strict quality and traceability requirements, where the addition rate and integration into multistep syntheses are precisely controlled from pilot scale to commercial API output.

Industry compliance standards

• International Council for Harmonisation (ICH) Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia Monograph 09/2017:2570
• United States Pharmacopeia (USP) standards where applicable
• Chinese Pharmacopoeia (ChP) active ingredients regulations
• cGMP (current Good Manufacturing Practice) system audits

Typical usage ratio

• Stoichiometric amount determined by the target API synthesis; typically 0.95–1.05 molar equivalent relative to coupling agents or precursors, adjusted based on final batch yield and chiral conversion.

Downstream process integration

• Introduced during designated stages of stepwise or convergent organic synthesis, often post-chiral resolution or as a building block for key imidazole ring formation, followed by purification and salt formation before isolation of bulk API.

Final product types

• Finished non-steroidal antiandrogen APIs (e.g., Bicalutamide for use in oral solid dosage preparations)
• Bulk API shipments for further pharmaceutical formulation

2. Finished Dosage Form Manufacturing: Oncology Tablet Production

Pharmaceutical enterprises manufacturing oral oncology treatments utilize this raw material as an input for the preparation and compounding of oral solid dosage forms. The product’s chiral consistency supports uniformity and bioequivalence of tablets, which are subject to batch release under regulated pharmaceutical environments. The handling, blending, and tableting processes rely on robust supplier-to-plant material specifications throughout the workflow, from API blending to finished blister packing.

Industry compliance standards

• EU GMP Annex 13: Manufacture of Investigational Medicinal Products
• US FDA 21 CFR Part 210/211: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs
• WHO Prequalification Programme Technical Guidance on Finished Pharmaceutical Products

Typical usage ratio

• Content of API per finished tablet: usually 50 mg per tablet; overall blending ratios determined by batch specifications, with variations for single-dose and multi-dose regimens (commonly between 2–6% w/w depending on excipient ratio).

Downstream process integration

• API is milled and blended with excipients using high-shear mixers, then granulated and compressed into tablets; downstream coating and blister packaging complete the process before distribution.

Final product types

• Packaged bicalutamide tablet forms for prescription oncology use
• Hospital and retail pharmacy solid oral medicinal products

3. Contract Manufacturing for Generic Oncology APIs

Global contract development and manufacturing organizations (CDMOs) incorporate this chiral intermediate as part of technology transfer and scale-up programs for generic antiandrogen compounds. The ability to achieve reproducible enantiomeric excess and impurity profiles influences regulatory submissions and batch certification, especially for export to markets requiring rigorous generic equivalency assessment. Handling this stage requires close alignment of analytical specifications and in-process control steps with client documentation.

Industry compliance standards

• WHO GMP guidelines specific to API and generic medicinal ingredients
• US FDA DMF (Drug Master File) requirements (Type II: Drug Substance)
• EU DMF/CEP (Certificate of Suitability to the Monographs of the European Pharmacopoeia)
• ISO 9001:2015 quality management systems for manufacturing documentation and traceability

Typical usage ratio

• Batch-dependent; generally 0.98–1.02 molar equivalent intake per final generic API output, modulated based on client process route and regulatory specifications requiring consistent impurity profiling.

Downstream process integration

• Material enters API production during chiral step or as late-stage precursor, followed by reactions leading to generic API isolation, crystallization, QC, and packaging into export-compliant lots.

Final product types

• Generic antiandrogen APIs for downstream formulation or export
• Bulk active ingredient lots for regulatory and dossier submission

4. Clinical Development Supply for Oncology Research Programs

CROs and pharmaceutical R&D groups source this raw material under GMP and investigational supply systems supporting phase I–III clinical trial materials. The ability to guarantee both chiral purity and documentation traceability under strict research protocols distinguishes supply for investigational use from commercial manufacture. Each batch typically undergoes additional analytical verification and tailored packaging to support clinical formulation work and accelerate project timelines in pharmaceutical R&D pipelines.

Industry compliance standards

• ICH Q11: Development and Manufacture of Drug Substances
• Good Clinical Practice (GCP) for investigational medicinal products
• US FDA Guidance for Industry: INDs for Phase 2 and 3 Studies
• EU Clinical Trials Regulation (CTR) 536/2014

Typical usage ratio

• Based on investigational batch requirements; common ranges are 0.8–1.2 molar equivalents per target dose formulation batch, periodically adjusted to match protocol-driven trial material requirements.

Downstream process integration

• Supplied as a GMP traceable intermediate or small-batch API, integrated at trial dose scale into research-grade tablet, capsule, or suspension formulations—often produced under tightly controlled pilot plant or research facility environments.

Final product types

• Clinical trial samples of antiandrogen medicinal products
• Research-use only (RUO) grade solid or liquid oral preparations for human medicinal studies